Navigation Links
Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimer's Disease
Date:9/4/2012

ALISO VIEJO, Calif., Sept. 4, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

"Alzheimer's disease can cause a person to exhibit marked behavioral changes that are difficult for caregivers to manage. These symptoms can include agitation, hostility, anger, and aggression, with most patients exhibiting some or all of these symptoms during the course of the disease," said Jeffrey Cummings, MD, Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic. "As the disease progresses, behavioral symptoms often increase in frequency and severity. With no approved therapies for agitation associated with dementia, managing these symptoms can be challenging. This trial is an important initial step in potentially providing a therapy to help manage symptoms of agitation in Alzheimer's disease."

The objectives of this proof of concept study are to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of agitation in Alzheimer's patients. The trial is a multicenter, randomized, double-blind, placebo-controlled study that is expected to enroll up to 200 Alzheimer's patients in the United States. Eligible patients will be randomized to receive either AVP-923 or placebo for 10 weeks. The main efficacy measure is the Neuropsychiatric Inventory or NPI. Secondary outcome measures include assessments of disease severity, behavioral abnormalities, cognition, activities of daily living, quality of life and caregiver strain. Standard safety assessments will also be conducted.

Jeffrey Cummings, MD is a paid consultant of Avanir Pharmaceuticals, Inc. In addition, Dr. Cummings is the inventor of the
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present at Three Conferences In May
6. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
7. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
8. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
9. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
(Date:11/24/2014)... The Female Health Company (NASDAQ-CM: FHCO), today ... to discuss its operating results for the fourth quarter ... December 2, 2014 at 11:00 a.m. Eastern Standard Time ... earlier the same day. Shareholders and other ... dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2
... SAN FRANCISCO, Calif., May 16, 2011 diaDexus, Inc. (OTC ... on the development and commercialization of patent-protected in vitro ... announced financial results for the first quarter of 2011. ... were $3.3 million, representing 25% growth over total revenues of ...
... Oncology molecules in development will be presented during the 47th ... held in Chicago, Ill. from June 3 – 7, 2011. ... industry, with more than 30 molecules in development to treat ... these pipeline molecules are being evaluated for certain biomarkers or ...
Cached Medicine Technology:diaDexus, Inc. Reports 2011 First Quarter Financial Results 2diaDexus, Inc. Reports 2011 First Quarter Financial Results 3diaDexus, Inc. Reports 2011 First Quarter Financial Results 4diaDexus, Inc. Reports 2011 First Quarter Financial Results 5Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 2Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 3
(Date:11/24/2014)... SafeHandles™ announced that they will be ... Begley Jr, airing via Discovery Channel. Dates and show ... passive, non-invasive, replaceable, and affordable germ protective device. This ... sleeves and adhesives to promote hand hygiene in high ... of SafeHandles is the desire to make a positive ...
(Date:11/24/2014)... 24, 2014 "My friend was killed ... to cross the street in his motorized wheelchair," said ... him. I came up with this idea so that ... , He developed the Safety Lites to make a ... conditions. The device ensures that motorists can see the ...
(Date:11/23/2014)... November 23, 2014 The report, ... 2006 to 2020 - Asia-Pacific” provides quantitative analysis ... market segments: minimally invasive body contouring devices, non-invasive ... analysis includes market size data by revenue and ... following countries: China, Japan, South Korea, Australia and ...
(Date:11/23/2014)... friends have more influence on teens, alcohol use than ... "We,ve known for a long time that ... use, but there are no common studies that distinguished ... influence on those decisions," Jonathon Beckmeyer, an assistant professor ... a university news release. Beckmeyer analyzed data gathered ...
(Date:11/23/2014)... show thanks to new and old customers, iFitDress.com has ... for weddings. Customers who need custom outfits can talk ... dress manufacturer, and it is among the ones which have ... long time. The CEO of this company says, "iFitDress.com is ... buy not only a beautiful dress, but also a piece ...
Breaking Medicine News(10 mins):Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... Demonstrates a 20-Meter Improvement in Six-Minute Walk ... Distance ... Time on November 1, 2007, SILVER SPRING, Md., Nov. 1 ... Rx, Inc., announced today the completion of their TRIUMPH-1 Phase 3,trial ...
... Calif., and WHITEHOUSE STATION, N.J., Nov. 1, Dynavax ... Co., Inc. (NYSE: MRK ) today announced ... develop HEPLISAV(TM), a,novel investigational hepatitis B vaccine, which ... clinical trial involving adults and in,patients on dialysis. ...
... 1 The makers of the WaveSense line ... Claudio,Carboni, formerly of Menarini Diagnostics, has joined as ... WaveSense Europe will,distribute the company,s high accuracy, WaveSense ... market both directly and through local,partners. Carboni ...
... Upload Video Confessions/ Testimonials for ... PHILADELPHIA and LONDON, Nov. 1 Thomson,Scientific, ... ; TSX: TOC) and,leading provider of information solutions ... the launch of its new campaign,"Confessions ... of ...
... (MHS), a not-for-profit health care system with hospitals ... it has selected,Integrated Healthcare Holdings, Inc. (IHHI) to ... partially physician-owned publicly traded hospital management,company, owns and ... total of,770 beds, 2787 employees and 1725 active ...
... Oct. 31 Always Best Care Senior,Services has expanded ... Living Placement Service, and Personal Response Company, is,proud to ... Always Best Care,Senior Services for outstanding care. For over ... our work - a sincere concern for,the betterment of ...
Cached Medicine News:Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 2Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 3Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 4Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 5Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 6Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 2Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 3Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 4Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 5Health News:Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Memorial Health Services Announces Sale of Anaheim Memorial Medical Center 2Health News:Announcing Always Best Care Senior Services Expansion Into San Diego, California 2
... smallest handheld oximeters available, Datex-Ohmeda s TuffSat ... home care, transport, and EMS. TuffSat comes ... (relative perfusion index measurement) a quick, ... reflection of perfusion at the sensor site. ...
... the power of clinical information. , ... of clinical connectivity solutions that help you ... high-quality patient care. You will have access ... to share it with your care team ...
... For safe and easy patient monitoring during MRI, ... the special needs of the MRI environment. It ... during MRI, promoting safety and flexibility., ,Though ... offers all the key benefits of the S/5 ...
... Compact and comprehensive solution for ... Arrhythmia Workstation (ARRWS) provides one compact, ... telemetry monitored patients. It connects to ... analysis for up to 16 beds., ...
Medicine Products: